BioSpace News Archive

FDA

Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for 124 I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin amyloidosis (ATTR).

August 8, 2022
·
4 min read
Business

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin ® Gel.

August 8, 2022
·
25 min read
Business

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress updates for the second quarter ending June 30, 2022.

August 8, 2022
·
7 min read
Drug Development

CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension

CinCor Pharma, Inc. (“CinCor”) announced today the topline results and successful completion of its Phase 2 BrigHtn trial evaluating the efficacy and safety of baxdrostat.

August 8, 2022
·
11 min read
Business

LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update

LENSAR, Inc. today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.

August 8, 2022
·
12 min read
Business

Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update

Annovis Bio, Inc. today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.

August 8, 2022
·
4 min read
Business

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

Gain Therapeutics, Inc. today announced its financial results for the second quarter ended June 30, 2022, and highlighted recent corporate progress.

August 8, 2022
·
11 min read
Business

Vaxart Appoints W. Mark Watson to its Board of Directors

Vaxart, Inc. (NASDAQ: VXRT) today announced that W. Mark Watson was appointed to the Company’s Board of Directors, effective August 4, 2022.

August 8, 2022
·
6 min read
Business

Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical and Distribution Partner Marathon Medical Awarded Contract to Provide SAMI Dialysis Devices to the US Department of Veterans Affairs

Spectral Medical Inc. today announced that Dialco, along with its distribution partner, Marathon Medical Corporation, have been awarded a five year Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide SAMI CRRT (chronic renal replacement therapy) dialysis devices and associated maintenance services to the United States Department of Veterans Affairs’ (VA) national healthcare system.

August 8, 2022
·
5 min read
The Parenteral Drugs Market Is Poised To Reach A Staggering Valuation Of US $ 802Bn By The End Of The 2029; States Fact.MR

Fact.MR – A Market Research and Competitive Intelligence Provider: The global parenteral drug market is expected to register growth during the forecast period.

August 8, 2022
·
7 min read